Arata Azuma

Dec 4, 2024 | bmjopenrespres.bmj.com | Luca Richeldi |Arata Azuma |Vincent Cottin |Michael Kreuter

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive disease associated with a decline in lung function and early mortality. In a phase II trial, treatment with the oral preferential phosphodiesterase 4B inhibitor, BI 1015550, prevented a decline in lung function over 12 weeks and had an acceptable safety profile in patients with IPF, regardless of background use of antifibrotics, supporting phase III clinical development.

Aug 13, 2024 | digitalcommons.library.tmc.edu | Toby Maher |Shervin Assassi |Arata Azuma |Vincent Cottin

INTRODUCTION: Progressive pulmonary fibrosis (PPF) includes any diagnosis of progressive fibrotic interstitial lung disease (ILD) other than idiopathic pulmonary fibrosis (IPF). However, disease progression appears comparable between PPF and IPF, suggesting a similar underlying pathology relating to pulmonary fibrosis. Following positive results in a phase II study in IPF, this phase III study will investigate the efficacy and safety of BI 1015550 in patients with PPF (FIBRONEER-ILD).

Jun 27, 2024 | bmjopenrespres.bmj.com | Toby Maher |Shervin Assassi |Arata Azuma |Vincent Cottin

Interstitial lung disease Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD) Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service.

Jun 27, 2024 | bmjopenrespres.bmj.com | Luca Richeldi |Arata Azuma |Vincent Cottin |Michael Kreuter

Methods and analysisThis multicentre, double-blind, randomised, placebo-controlled trial is investigating the efficacy and safety of BI 1015550 in patients with IPF stratified by use of background antifibrotics over at least 52 weeks (EudraCT: 1305-0014; ClinicalTrials.gov: NCT05321069). The trial began in September 2022 and is estimated to complete in November 2024.

Feb 19, 2024 | futuremedicine.com | Toby Maher |Arata Azuma |Vincent Cottin |Shervin Assassi

This is an abstract of the Plain Language Summary of Publication article. To read the full Plain Language Summary of this article, click here to view the PDF. Link to original articles hereLink to original articles hereAcknowledgmentsThe authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE). The authors did not receive payment related to the development of the manuscript.